Allurion Technologies, INC

Allurion Technologies announced a debt restructuring through an exchange of common stock for pre-funded warrants and the termination of a prior purchase agreement.

Allurion Technologies announces the immediate resignation of CEO Shantanu K. Gaur, with COO Ojas Buch to manage daily operations.

Allurion Technologies, Inc. announced the resignation of director Douglas Hudson from its Board and Nominating and Corporate Governance Committee, effective June 30, 2026.

Allurion Technologies, Inc. announced the resignation of R. Jason Richey from its Board of Directors and as Chairperson of the Audit Committee, effective June 24, 2026.

Allurion Technologies, Inc. has implemented a 1-for-15 reverse stock split to regain compliance with NYSE listing standards and advance its relisting strategy.

Allurion Technologies, Inc. announced the dismissal of Deloitte & Touche LLP as its independent registered public accounting firm and the appointment of CBIZ CPAs P.C., citing material weaknesses in internal controls.

Allurion Technologies reports a significant revenue decline and net loss, triggering a 'going concern' warning while pursuing strategic restructuring and new financing.

Allurion Technologies, Inc. filed an amended quarterly report for Q3 2024, restating financials due to accounting errors and announcing a significant workforce reduction.

Allurion Technologies, Inc. has restated its Q2 2024 financials due to material weaknesses in internal controls, while facing a sales suspension in France and a NYSE delisting notice.

Allurion Technologies, Inc. filed an amended quarterly report to restate its Q1 2024 financial statements, revealing material weaknesses in internal controls and a significant revenue decline.

Allurion Technologies reports a significant revenue decline and increased net loss, leading to a major restructuring and raising substantial doubt about its ability to continue as a going concern.

Allurion Technologies, Inc. restated prior financial statements, revealing significant losses and material weaknesses in internal controls, while raising capital and addressing regulatory hurdles.

Allurion secured FDA PMA approval for its swallowable gastric balloon but reported a 53% revenue decline, going‑concern doubts, NYSE delisting proceedings, and tight liquidity as it restructures and pursues financings.

Allurion Technologies, Inc. has filed an amended annual report, restating its 2023 financial statements due to accounting errors and disclosing material weaknesses in internal controls, alongside a significant net loss and going concern warning.

Allurion Technologies, Inc. restates prior financial statements due to material weaknesses in internal controls, reporting a reduced net loss for 2024 but facing ongoing liquidity concerns and NYSE compliance challenges.

Allurion Technologies plans to submit its final FDA module after positive AUDACITY trial results, resumes sales in France, and explores combination therapies to combat obesity.

Allurion Technologies has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

Allurion Technologies experienced a 17% year-over-year revenue decline in 2023, alongside a significant increase in net losses, as it continues to develop its weight loss platform.

Rtw Investments, Lp and 1 other reported changes in beneficial ownership of Allurion Technologies, Inc. common stock on July 21, 2026.

Allurion Technologies Director Michael R. Davin reported a series of stock transactions, including gifts and sales, following a reverse stock split.

RTW Investments and affiliated funds acquired common stock and warrants in Allurion Technologies through a private placement at $1.67 per share.

RTW Investments and its affiliated funds converted $5 million of convertible notes into Allurion Technologies common stock at $3.35 per share.

Allurion Technologies' CEO, Shantanu Gaur, recently purchased 8,000 shares of the company's common stock at an average price of $3.0605 per share.

RTW Investments, LP, along with affiliated funds, acquired a significant stake in Allurion Technologies through the conversion of convertible notes and other transactions, as detailed in a recent SEC Form 4 filing.

Allurion Technologies, Inc. issued a supplement to its 2025 proxy statement, clarifying routine and non-routine proposals for broker voting at the upcoming Annual Meeting.

Allurion Technologies, Inc. is seeking stockholder approval for a reverse stock split, an amended equity incentive plan, option repricing, and the issuance of shares for debt conversion to address NYSE listing requirements and enhance long-term value.

Allurion Technologies has postponed its special meeting of stockholders to April 10, 2025, to allow for more proxy solicitation and broader stockholder participation.

Allurion Technologies is holding a special meeting to seek stockholder approval for several proposals related to warrant repricing, share issuance, and note conversion price amendments to improve its financial flexibility and meet NYSE listing requirements.

Allurion Technologies is asking stockholders to approve a reverse stock split to meet NYSE listing standards and several proposals related to share issuances at its upcoming annual meeting on December 11, 2024.

Allurion Technologies is seeking to raise capital through an offering of common stock, pre-funded warrants, and common stock purchase warrants.

Allurion Technologies plans to raise capital through an offering of common stock, pre-funded warrants, and common warrants.

Allurion Technologies, a medical device company focused on weight loss solutions, has filed a registration statement for a potential offering of up to $30 million in common stock, pre-funded warrants, and common warrants.

Allurion Technologies files an amendment to its S-1 registration statement to register the sale of up to 65,211,325 shares of common stock by a selling securityholder.

Allurion Technologies has filed an amendment to its S-1 registration statement, covering the potential resale of up to 65,211,325 shares of common stock by a selling securityholder.

Allurion Technologies announces a public offering of up to $20 million of common stock and warrants to fund clinical trials, commercial sales, and research and development.

RTW Investments, LP and Roderick Wong, M.D. have filed an amendment to their Schedule 13D, detailing a recent share exchange and warrant agreement with Allurion Technologies, Inc.

RTW Investments, LP and its affiliates updated their beneficial ownership in Allurion Technologies, Inc. to 39.4% following an increase in the issuer's outstanding shares.

Allurion Technologies, Inc. announced a debt-for-equity exchange and a private placement, strengthening its financial position and governance with RTW Investments.

RTW Investments and its affiliated funds converted $5.0 million in principal amount of notes into 1,492,539 shares of Allurion Technologies, Inc. common stock, increasing their beneficial ownership.

RTW Investments, a significant shareholder in Allurion Technologies, has increased its beneficial ownership to 34.1% by converting $5.0 million in notes into 1,492,539 common shares, following an amendment to their note purchase agreement.

RTW Investments, LP and its affiliates have increased their beneficial ownership in Allurion Technologies, Inc. to 17.6% of the common stock outstanding.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% of Allurion Technologies, Inc.'s common stock as of March 31, 2025.

Leavitt Equity Partners and its affiliates have disclosed a beneficial ownership of 7.8% in Allurion Technologies, Inc., holding 462,762 shares of common stock.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a shared beneficial ownership of 4.99% of Allurion Technologies, Inc.'s common stock as of January 31, 2025.